Navigation Links
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
Date:7/16/2008

Raptor to Support Phase 2a Clinical Trial at UCSD

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the execution of a collaboration agreement (the "Agreement") with the University of California, San Diego ("UCSD") to include a Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate ("Cysteamine") in adolescents diagnosed with Non-Alcoholic Steatohepatitis ("NASH"). NASH is a progressive form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, and ranks as one of the leading causes of cirrhosis of the liver in the U.S.

Under the terms of the Agreement, clinical researchers from UCSD will perform the Phase 2a study at the University's General Clinical Research Center, and Raptor will provide funding and clinical supply of Cysteamine. In March 2008, Raptor acquired an exclusive, worldwide license to certain intellectual property and development rights from UCSD surrounding the use of Cysteamine as a potential treatment for NASH.

A rapid-release form of Cysteamine is currently approved for sale by the U.S. Food and Drug Administration ("FDA") for the treatment of nephropathic cystinosis, a rare, genetic lysosomal storage disease. Raptor is currently developing DR Cysteamine, a proprietary, delayed-release formulation of Cysteamine, designed to improve bioavailability and potentially reduce side effects associated with the presently marketed form.

Ted Daley, President of Raptor's clinical division stated, "We look forward to working with UCSD, one of the leading research universities in the nation, under this collaboration agreement. The University's clinical researchers have specific expertise in treating NASH patients, and have also worked extensively with Cysteamine. We are fortunate to work with this team to investigate our drug candidate
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Raptor Pharmaceuticals Provides Update of Product Programs
3. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
6. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
7. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
10. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... , CARTERSVILLE, Ga. ; June 2 ... Women (GASC) – Georgia ,s first fully ... minor gynecological surgeries in a true ... facility specializes in laparoscopic and other highly advanced, ...
... (Nasdaq: FHCO ) announced that it has fulfilled an order for 3.5 million ... World Cup. The 2010 World Cup will take place in The Republic of ... . , , , ... three million tickets to the games, is expected to flood the country with visitors. ...
Cached Medicine Technology:New Georgia Advanced Surgery Center Provides Women Many Unique Benefits 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 3
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Integrated Medical,Systems, Inc., a medical technology systems integrator ... that it has received,510(k) clearance from the U.S. ... 1000(TM) "suitcase" intensive care unit (ICU)., "FDA ... accomplishment for the,company as we continue to demonstrate ...
... PhD.,co-founder and Chief Scientific Officer of Posit Science, has ... announcement by the Institute,today. Dr. Merzenich is one of ... a highly selective process that recognizes,people who have made ... care, and public health. Election is considered one of ...
... Oct. 13 The 2008 NCPA Digest,sponsored by ... 110th Annual,Convention. The Digest has been published annually ... portrait of the financial state of,independent community pharmacy ... an inside look into how the Medicare Part ...
... Knowledge Sharing among Physicians, MOUNTAIN VIEW, Calif., ... the healthcare IT market, Frost & Sullivan recognizes,Infor-Med, ... Sullivan Award for,Technology Innovation for its novel Praxis(R) ... EMR Knowledge Exchanger., The Praxis(R) EMR system ...
... 13 NeoVista, Inc., presented,yesterday the anatomic ... on choroidal neovascular lesions in an analysis ... 26th Annual Meeting. The,12-month data presented by ... Houston, Texas, demonstrated anatomic improvements on both,angiography ...
... neonatology fellows have been awarded grants designed to ... follow-up care of the premature infant as part ... MedImmune,s commitment to expanding research within pediatric medicine, ... totaling $175,000 in research funding. The five recipients ...
Cached Medicine News:Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3Health News:Merzenich Elected to Institute of Medicine 2Health News:Merzenich Elected to Institute of Medicine 3Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 2Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 3Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: